




LTrachea-guided generation: De´ja` vu all over again?
Paolo Macchiarini, MD, PhDSee related articles on pages
124 and 147.
From the Department of Thoracic and Vas-
cular Surgery, Heidehaus Hospital, Han-
nover Medical School, Hannover, Ger-
many.
Received for publication Nov 12, 2003; re-
visions received Nov 19, 2003; accepted for
publication Nov 24, 2003.
Address for reprints: Paolo Macchiarini,
MD, PhD, Department of Thoracic and
Vascular Surgery, Heidehaus Hospital
(Hannover Medical School), Am Leineufer
70, 30419 Hannover, Germany (E-mail:
pmacchiarini@compuserve.com).
J Thorac Cardiovasc Surg 2004;128:14-6
0022-5223/$30.00
Copyright © 2004 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2003.11.06914 The Journal of Thoracic and CardiovTracheal surgery has matured to include techniques able to cure mostlesions involving approximately half of the tracheal length in adultsand probably a third in small children. Age, body build, localanatomy, type of pathology, and previous treatment may cause theselimits of resection to fluctuate, but a safe primary reconstruction isalmost always possible provided the surgeon respects the well-
known surgical principles and uses anatomic mobilization procedures.1 The com-
plex problem of congenital tracheal stenosis has also been solved by slide tracheo-
plasty,2 and even those benign lesions that are too lengthy for safe reconstruction
nowadays can be successfully managed in the long-term with T-tubes or stents.3 It
therefore appears that the clinical need for tracheal replacement is restricted to
unresectable diseases—such as tracheopathia osteoplastica, relapsing polychrondri-
tis, Wegener granulomatosis, trauma and low-grade malignancies in adults, and
tracheal agenesis in neonates4—that are essentially treated with palliative measures
and immunosuppression. Despite this, experimental research to generate a func-
tional tracheal graft has been going on for a century and is currently under active
investigation. Unfortunately, no predictable and dependable replacement has yet
been found.5 This is not surprising, because an ideal graft must have some prereq-
uisites: lateral rigidity and longitudinal flexibility, complete air tightness, biocom-
patibility, nonimmunogenicity, nontoxicity, resistance to bacterial colonization,
freedom from the need for immunosuppression, permanent construction, ease of
implantation, and the ability to provide a platform of ciliated respiratory epithelium
resurfacing.
In this issue of the Journal, Kim and associates6 have combined the lessons
learned from the past with the exciting research field of tissue engineering and
experimentally developed a hybrid prosthetic graft that apparently fulfills almost all
requirements for an ideal tracheal substitute. Conceptually, their working hypothesis
is attractive. They first tissue engineered a viable autogenous mucosa by isolating
abdominal skin epithelial cells and seeding them on a polylactic glycolic acid
scaffold. Next, the autogenous mucosa was attached with biodegradable glue to the
luminal surface of a porous prosthesis framework made up of polypropylene mesh
reinforced with polypropylene rings. This artificial “hybrid” construct was then
incubated for 1 week in the peritoneal cavity of the host to promote vascularization
and maintain viability of the implanted tissue-engineered mucosa. One week later,
the prosthesis along with the omentum was transposed into the thoracic cavity and
used to replace a tracheal defect 5 cm in length (10 rings). Early (2 months)
bronchoscopic results showed no anastomotic stenosis.
Tissue engineering applies the principles of engineering, material science, and
biology toward the development of biologic substitutes that restore, maintain, or
improve tissue function.7 This process of fabricating new, physiologic, functioning
tissues may be obtained by the (1) guided tissue regeneration with engineered
matrices alone, (2) injection of allogenic or xenogenic cells alone, or (3) use of cells
seeded on or within matrices (cell matrix construct), being the latter two approaches
the most common. The use of isolated cell or cell substitutes avoids potential
surgical complications and allows cell manipulation before injection but has the
drawbacks of possible rejection or loss of function.8 The use of seeded matrices, the
most common method in tissue engineering, is particularly fascinating because these
structures are biocompatible, bioabsorbable, nonimmunogenic, supportive of cell
attachment and growth, and inductive of angiogenesis. They may be created either







Lby isolating the cells from host’s body with a permeable
membrane allowing exchange of nutrients (closed system)
or by culturing in vitro the isolated cells and seeding them
onto a scaffold, either synthetic or natural, that is implanted
into the host after a given cultivation time (open system).9
Cells used in tissue engineering can be derived from nu-
merous sources, including primary tissues, cell lines, and
stem cells, and they may be allogenic, xenogenic, synge-
neic, or autologous. Ideally, the cells should be easy to
harvest, highly proliferative, nonimmunogenic, and able to
differentiate into a variety of cell types with specialized
functions.10 Having said that, it appears that the methodol-
ogy used in Kim and colleagues’ research6 is not tissue
engineering but rather guided tracheal tissue generation,11
because the tissue-engineered mucosal framework “remod-
els” to achieve a function only after its implantation into the
native tracheal bed, which ultimately serves as a natural
“bioreactor.” Isn’t this like de´ja` vu to some extent? “A
polypropylene mesh [de´ja` vu] was covered with a tissue-
engineered mucosa [new concept] used to replace 5-cm
tracheal length in dogs [de´ja` vu].”10
This study adds useful confirmation about the effective-
ness of tissue engineering, but the data should be reviewed
and interpreted cautiously. First, the authors provide no
morphologic, functional, biochemical, and immunologic
data supporting the generation of a respiratory mucosa and
its viability during the study period. Second, it is well
known that a tissue-engineered cellular graft of larger than
0.8 mm in diameter needs vascularization to maintain via-
bility after implantation into the host. However, the revas-
cularization process usually begins within the first 2 weeks
and flourishes within the eighth week of implantation.12
One might therefore speculate that an implantation time of
1 week is almost certainly too short for sufficient revascu-
Figure 1. Chamber slide showing two porcine smooth myocytes
after 2 weeks in culture (200 magnification).larization of small-diameter grafts. Third, the authors argue
The Journal of Thoracthat the hybrid prosthesis was implanted into the peritoneal
cavity mainly to promote the vascularization of the mucosa.
However, grafts implanted into the peritoneal cavity are
covered with a heavy vascularized epithelial layer, repre-
senting a foreign-body reaction encapsulating the implanted
graft. This reaction does not per se promote neoangiogen-
esis in the graft.13 Therefore it is highly questionable that
both the mucosal lining was directly vascularized during its
implantation into the peritoneal cavity and the hybrid pros-
thesis was viable and remained so at the time of transplan-
tation. Fourth, assuming, however, that the luminal surface
of the prosthesis was really covered with viable mucosal
cells (because of its indirect vascularization with the omen-
tum major), it is not unrealistic to speculate that it was either
resurfaced with respiratory epithelium grown in from the
anastomosis sites because of the short length (5 cm) of the
implant14 or the original autologous stratified squamous
epithelium regenerated to ciliated columnar epithelium just
because of the porous nature of the prosthesis used, a
common observation in the past.5 This is of clinical concern
because in the interval between the bioartificial graft im-
plantation and successful graft regeneration the luminal
surface of the tracheal implant does not possess the usual
physiologic properties,15 rendering it more susceptible to
inflammation, granulation tissue formation, infection, and
erosion. We therefore look forward to the long-term results
as to whether the respiratory epithelium reseeded the graft
surface after implantation. Fifth, if transposed to the clinical
Figure 2. Tissue-engineered functional cartilage. Porcine chon-
drocytes seeded on 3-dimensional biologic matrix are located in
lacunas and surrounded by newly synthesized collagen (100
magnification). Western blots showed functioning chondrocytes.scenario, the methods used would be inapplicable because





Lthe necessity of multiple general anesthetic procedures and
two abdominal operations, the short length of transplanted
grafts (5 cm, which has no potential clinical use), and, most
of all, the absence of an adequate blood supply, which has
been the major hurdle of autotransplanted free tracheal
segments of any significant length, despite muscular or
omental pedicles.16
So, what can we learn from this and what implications
does this study have for the current and future state of the art
of tracheal transplantation? Surgically placed porous pros-
theses (with and without epithelialization) have been unsuc-
cessful in human use16 basically because they are exposed
to a contaminated interface between air, chronically repair-
ing connective tissue, and epithelium. It is time to acknowl-
edge that they are biologically incompatible, in contrast to
vascular conduits placed in potentially sterile mesenchymal
tissue. My laboratory has traditionally been interested in
tracheal transplantation. After having experimentally devel-
oped the surgical technique for directly revascularizing
long-segment (9-11 cm) tracheal allografts,17 we have
shifted our efforts to the generation of a direct revascular-
ized tissue-engineered trachea because of the obvious ad-
vantages that this emerging technology has relative to tra-
cheal allotransplantation4 or any other available
alternative.14 The article by Kim and associates6 suggests
that engineering a “trachea” mucosa is feasible, shows the
limitation of tissue generation, and provides definitive and
indirect evidence that only a complete tissue-engineered
graft may substitute functionally for the native trachea.
However, this is the real “holy grail” of tracheal replace-
ment. The ideal functioning substitute must exhibit long-
term patency, and the critical issues in this area in many
ways are influenced by biomechanics and function. One of
the requirements is that it must avoid graft obstruction by
cicatrization, which requires a respiratory epithelium–like
inner lining (Video). It also must have mechanical strength
sufficient to operate at inspiratory and expiratory pressures.
Ideally, however, it must be more than the sum of these
qualities. It also must have contractile properties that match
those of the native trachealis muscle being replaced (Figure
1). Finally, to have a clinical impact it must be sufficiently
long and adaptable to changing respiratory flow conditions
16 The Journal of Thoracic and Cardiovascular Surgery ● July 2(Figure 2), a function which in itself can be viewed as
biomechanical in nature. To achieve this requires having, as
part of the construct, a blood supply. Only if an engineered
tracheal substitute possesses all of these functional charac-
teristics can one say that the functionality exhibited by a
native trachea is being mimicked.
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